Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast 

Reuters was ahead of competitors with news that Eli Lilly’s unscheduled trading update revealed lower-than-expected fourth-quarter sales of the weight-loss drug Zepbound, causing the drugmaker’s shares to drop by 8%. This development had a significant impact on the market, highlighting the importance of timely and accurate information in the business and finance sector.

Full Article